We investigated the role of the complementarity determining region 1 (CDR1) of T cell receptor (TCR)/3 chain both in antigen/major histocompatibility complex I (MHC I) and in superantigen (SAg)/MHC II complex recognition. Residues 26 to 31 of the VB10 domain of a TCR derived from an Hl2Ka-restricted cytotoxic clone were individually changed to alanine, using sitedirected mutagenesis, and the mutated TCR/3 chains were transfected along with the wild-type TCR c~ chain into a TCRc~-/3-T hybridoma. These mutations affected antigen/H-2K a complex recognition, although to a different extent, as estimated by interleukin 2 production. Certain mutations also affected differently the recognition of two Staphylococcal toxins, exfoliative toxin and Staphylococcal enterotoxin C2, presented by HLA-DR1. Whereas mutation of residues D30 or T31 affect the recognition of both toxins, residues T26, L27, and H29 are critical for the recognition of only one of the SAgs. These observations demonstrate the participation of the CDR1 region in the recognition of peptide/MHC class I as well as SAg/MHC II complexes.
U
nlike Igs, which can recognize antigen in its native form, the TCR recognizes a peptide that is the product of antigen processing and that is trapped in the groove of the MHC molecule on the plasma membrane of a presenting cell (for a review, see references 1 and 2). However, the organization of rearranging gene elements and the primary amino acid sequence of the TCR are similar to those of Igs (3, 4). The conservation in c~ and/3 TCR chains of residues found to be crucial for the structure of the Ig variable domains, suggests that the three-dimensional structure of the TCR is similar to the known atomic structure of the Fab moiety (5). By analogy to the antigen binding site on Ig, three regions of TCR o~ and/3 chains, which are hypervariable and which correspond to the loops formed between/3 sheets, are named CDR1, CDR2, and CDR3. The last one is encoded by the V-(D)-J junction in cx and/3 TCR chains and is therefore the most variable one, whereas CDR1 and CDR2 are encoded in the genome by the V segment. A fourth hypervariable region (CDR4) was identified in the TCR/3 chain (6, 7) .
Based on this model of TCR structure and the known crystal structure of several HLA molecules, different groups (4-6) have proposed that the less variable CDR1 and CDR2 regions might make direct contact with the MHC molecules whereas the CDR3 region might make direct contact with the antigenic peptide. Consistent with this model, mutations of the CDR regions, especially in CDR3, cause a loss of recognition of the antigen/MHC complex (8) (9) (10) (11) (12) . However, to our knowledge, all of the data available until now concern TCR restricted to class II MHC molecule.
In the past few years, a distinct group of antigens has been described and termed superantigens (SAg) 1 (for a review see reference 13) . Several exotoxins of Staphylococcus aureus have superantigenic properties: activation of subsets of T cells expressing particular V/3 families and presentation in a site of the MHC class II molecule distinct from the peptide-binding pocket, in the absence of processing and of absolute allotype restriction (14) . Several studies have led to map critical residues for SAg recognition to the lateral solvent-exposed face of the Vfl domain, mainly in the CDR4 region (15) (16) (17) (18) (19) . However, there is recent evidence that other components of the TCK may also contribute to the interaction with the SAg/MHC complex (20) (21) (22) (23) . Moreover, although it is generally assumed that the surface of the TCK that engages MHC in the complexes with SAg is the same one that contributes to MHC binding in conventional peptide/MHC complexes, experimental data for this point are scarce.
The results obtained in this study identified residues in the Vfll0 chain CDR1 region of a H-2Kd-restricted TCR that are important both for specific peptide/MHC class I and/or SAg/MHC class II complex recognition.
Materials and Methods
Transfecting Cells andPlasmids. The 58 TCR ce-~-cell line derived from DO.11.10 T hybridoma was previously described (24) . It was transfected by electroporation with plasmid pCA208 containing the Lyt2.2 gene and thegpt selective marker (25) . Sdection was done in the presence of mycophenolic acid (2.0 #g/ml), xanthine (250 #g/ml) and hypoxanthine (15 #g/ml). After cloning and subdoning, one CD8 + done denoted 3D1 was selected for transfection with cDNAs encoding the wild type (wt) or mutated (see below) Cw3/1.1 TCR c~ and ~ chains. A full-length cDNA corresponding to the TCIL ce chain present in Cw3/1.1 cytotoxic clone (26) was subdoned into the SalI/BamHI opened plasmid pHBAPr-l-neo (27) . Similarly, a fuiLlength cDNA corresponding to the TCR ~ chain found in Cw3/1.1 was subcloned into SalI/BamHI opened plasmid pHBApr-l-neo. To facilitate further handling of the TCR VB region, an XhoI site was engineered at the J~/CB junction. This process resulted in the substitution of an isolencine (ATA) by a leucine (CTC) at position 116A (see Fig.  1 ). Linearized plasmids pH~Apr-l-neo/Cw3~ and pH~APr-1-neo/Cw3~ were cotransfected with plasmid pCA262 containing the cDNA of murine CD3 ~'chain (28) . Transfectants were selected in 1.6 mg/ml of geneticine G418-sulfate (GIBCO BRL, Gaithersburg, MD) and screened for TCR expression by flow cytometry with a FITC-conjugated anti-CD3 mAb (2Cll, Pharmingen), using a FACScan | (Becton Dickinson & Co., Mountain View, CA). Subclones expressing high levels of TCg were isolated by flow cytometry sorting using 2Cll-FITC anti-CD3 mAb (Pharmingen, San Diego, CA) in a FACStar | (Becton Dickinson & Co. Site-directedMutagenesis ofTCR V~. The full-length Cw3 TCR cDNA was introduced into the SalI-BamHI open plasmid pBSK* (Stratagene, La Jolla, CA). The VB10-D~I-J~I.2 segment was then excised using SalI and XhoI restriction enzymes, from plasmid pBSK+Cw3~. The purified fragment served as template in recombinant PCR, as previously described (29) , for the generation of the single residue Ala-substituted mutants of the CDR1 fl region. The SalI/XhoI-digested PCIL products were cloned into the Sall/XhoI-digested and -purified pBSK § containing the TCR fl constant region. After sequencing, mutant (as well as wt) Cw3 TCR fl cDNAs were subcloned into the SalI/BamHI site of the expression vector pH APr-l-neo (27) .
Antibodies. 2Cll-FITC (anti-CD3) mAb and H57-biotinylated (anti-Cfl) mAb were purchased from Pharmingen, and 53-6.7-FITC anti-Lyt2 mAb from Becton Dickinson & Co. Anti-Vfll0 and anti-V~8 stainings were done with supematants of B21.5 and B21.14 hybridomas, respectively (30), using fluorescein-conjugated mouse anti-rat antiserum from Immunotech (Marseille, France), as secondary reagent.
Activation of Transfected Clones. Transfectants were grown in complete 10% FCS RPM11640 (GIBCO BRL) without G418 for 48 h before assay. 105 irradiated H-2K d expressing P815 cell line (10,000 tad) were plated into 96-well plates (Costar Corp.) and incubated for 3 h with 10 -4 M Cw3(170-179) peptide (Neosystem Laboratories SA, Strasbourg, France) at 37~ 105 transfected TCR § clones were then added in triplicates. Alternatively, 105 transfected clones were plated into 96-well microcuhure plates (Costar Corp.) previously incubated at 4~ overnight with purified 2Cll (anti-CD3) or H57 (anti-Cfl) mAbs at the indicated concentrations, or with 10/~g/ml of mouse anti-rat antiserum (Immunotech), washed three times with PBS, and then incubated for 1 h with complete medium (10% FCS) or with anti-VB10 (B21.5) rich supernatant, respectively. In some cases, PMA (Sigma Chemical Co., St. Louis, MO) was added in a final concentration of 10 ng/ml. The T hybridoma 9.4, product of the fusion of the CD8 + cytotoxic clone, Cw3/1.1 with the 58 TCK cx-fl-hybridoma was used in SAg Normalization of the Activation Responses. The relative antigen (or SAg) recognition index, (estimated by I1.-2 production) was calculated as previously described (11) mouse (H-2 a) with a P815 cell line transfected with HLACw3 (P815-Cw3) (26) . The fine specificity of the Cw3/1.1 TCR for the Cw3 (170-179) peptide presented by H-2K d has been described (26) . Based on the predicted structure of the TCR V region (5), the CDR1 region of the Cw3/1.1 TCR V/~ chain should lie between residues 26 and 31 (numbered according to reference 34). The relevant features of the Cw3/1.1 TCR, including the amino acid sequence of its V/~10 segment, are displayed in Fig. 1 . Note that the last residue of the JB1.2 segment, an isoleucine, was replaced by a leucine in order to create an XhoI site, which allowed the excision of the VDJ(~ segment for mutagenesis. This conservative change is not likely to affect the specificity of the Cw3/1.1 TCR, inasmuch as leucines are found at very high frequency at this position (34) .
The expression of the accessory molecule CD8cr was shown to be necessary, in some cases, to endow a recipient T hybridoma with the specificity of the transfected CTL-derived TCR (25) . To optimize specific recognition, we therefore transfected the genomic DNA of the CD8o~ molecule into the T hybridoma 58 o~-/~- (24) . The cDNAs corresponding to the wt or mutated TCR/~ chain were then transfected into the established CD8 + TCR (x-/~-3D1 subclone, together with a wt TCR o~ chain cDNA.
The CD3 J'chain constitutes a limiting factor for the transport of the TCR complex to the plasma membrane (35) . To reach high levels of TCR expression in the 3D1 subclone, and because 58 c=-/~-expresses low levels of endogenous CD3 ~" (Malissen, B., unpublished observation), a plasmid driving the expression of the CD3 ~" chain was systematically cotransfected with the ones driving TCR o~ and/~ chains expression (data not shown).
The surface expression of CD8o~ and of the TCR cr (bottom left) H57-biotinylated (anti-Cfl), followed by labeling with streptavidin-phycoerythrin; (bottom left) B21.14 (antiVow8), followed by fluorescein-conjugated mouse anti-rat antiserum.
complex was analyzed by flow cytometry, using several mAbs: 2Cll (which recognize an epitope on the CD3 e chain), H57 (which is specific for the C region of the ~/chain), and an anti-Va8:B21.14 (30) . Fig. 2 shows the FACS | profiles of the WT.27 clone expressing a wt TCR after staining with mAbs directed to the CD8a, CD3e, Cfl, or Vc~8 molecule domains. Clones expressing the same or higher amounts of CD8 and TCR than the wt TCR transfectants, were kept for further assays. We also used a fourth mAb, B21.5, which discriminates between the two allelic forms of mouse VB10 (30) . This mAb recognizes Vfll0 b, which differs from Vfll0 ~ at positions 11, 14, 24, 28, 30, and 84 (36) (numbered according to reference 34). All the Vfll0 b CDR.1 mutants described here are recognized by the anti-Vfll0 b mAb (data not shown). This observation suggests that the alanine substitutions do not cause major change in the VB10 structure and that the CDR1 residues 28 and 30 do not contribute to the epitope defined by mAb B21.5.
The Effect of Alanine Substitution in the Cw3/1.1 TCR fl Chain on Anti-V~IO mAb-induced Activation. To check their functional capabilities, mutants were first tested for IL-2 production induced by different doses of plate-immobilized mAb. All mutants could be activated in this way to produce IL-2 when induced by an anti-Cfl mAb (H57). Moreover, the different CDR1 fl mutants, with the exception of G28A, displayed a similar pattern of activation when induced by antiCfl or anti-Vfll0 mAbs, comparable with that observed for the wild type TCR transfectants, as shown in Fig. 3 . Although mutant G28A is recognized by B21.5 mAb as well as the other mutants (data not shown), it was found to be more sensitive to anti-Vfll0 mAb-induced activation. These results further support the notion that the alanine substitutions did not grossly disrupt the structure and function of the mutated TCR.
Specific Peptide/MHC I Recognition by the Cw3/1.1 TCR ~Mutants. The mutants were further tested for IL-2 production upon presentation of the Cw3(170-179) peptide by the H-2Kd-expressing P815 cell line. Only T26A and L27A mutants gave detectable responses (Table 1 ). The amount of IL-2 secreted by mutants G28A, H29A, D30A, and T31A were <0.07-0.16 U/ml, the minimum detectable level, depending on the experiment. As detailed in Materials and Methods, we normalized the response to the Cw3 peptide/K a of each tested done in relation to its response to one anti-CD3 (2Cll) or one anti-Cfl (H57) mAb. In an attempt to maximize the T hybridoma response, 10 ng/ml of PMA was added to the cultures. This increased the IL-2 secretion in response to antigen or anti-TCIL mAbs 2-10-fold. Nevertheless, IL-2 production by the G28A, H29A, D30A, and T31A mutants in response to Cw3 peptide/K d was not detectable even in the presence of PMA (Table 1) . In summary, alanine substitutions at CDR1 B positions 26 or 27 partially reduced the peptide/MHC recognition, whereas substitutions at positions 28, 29, 30, and 31 abolished recognition in our system.
Superantigen-induced Activation of Cw3/1.1 TCR ~ Mutants. We next tested the effect of the alanine substitutions Table 2 . Responses to SAg were normalized with respect to the activation induced by anti-C~/mAb, as above. All the CDR1 mutants, with the exception of G28A, have a reduced response to at least one of the superantigenic stimuli. It is interesting to note that whereas the alanine substitutions at positions 26 or 29 severely affected SEC2 recognition, substitution at position 27 almost abolished the response to ExT, without affecting SEC2 recognition. On the other hand, the recognition of SEC2 and ExT by mutants D30A " 10 s CDRI~/mutated or wt transfectants were cocultured with 105 K d+ P815 cells, in the presence of 10 -4 M ng/ml of PMA, for 24-36 h. I1.,2 production was estimated in a CTLb2 assay.
Anti-C~ (H57) or anti-CD3 (2Cll) mAbs were plated at 30.0-0.0137/~g/ml, after a threefold dilution. S The relative antigenic response was calculated as described in Materials and Methods.
of Cw3 (170-179) peptide and 10 and T31A is reduced to the same extent, D30A having more pronounced effects. A summary of the data is shown in Fig. 4 .
SAg Presentation by Different HLA-DR Alleles.
To obtain more information about TCR/SAg-MHC II interaction, presenting cells expressing other MHC II molecules were used for SAg presentation. Fibroblast L cell lines transfected with different alleles of HLA-DK (DRB1*1101, DRB1*1102, DRB1*1301, DILB1*1302), or with mutated HLA-DR (DRBl*1101 F67I and DRBl*1104 F67I) (31) were tested for ExT and SEC2 presentation to the wt Cw3/1.1 TCKbearing hybridoma 9.4. Results are shown in Table 3 . Three of these HLA-DK molecules were ineffective (DRB1*1301, DRB1*1302) or very poor presenters (DILBl*1102) for SEC2 and ExT to the VB10 + 9.4 hybridoma, although all of * 10 s CDR1/~ mutated or wild type transfectants were cocultured with 10 s DR-transfected L cells, in the presence of 10/~g/ml toxins, for 24-36 h. IL-2 production was estimated in CTLL-2 assay. Anti-Cfl (H57) or anti-CD3 (2Cll) mAbs were plated at 30.0-0.0137/~g/ml, after a threefold dilution. $ The relative superantigenic response was calculated as described in Materials and Methods. or ExT (T26, L27, and H29) are predicted to lie in the part of the CDR1 loop that faces the CDR4 region, whereas residues D30 and T31 which affect recognition of both toxins, are at the COOH-terminal end of the CDR1 region, closer to the CDR2 and CDR3 loops.
Discussion
In the absence of direct structural data, several groups (4-6) have proposed models of the TCR/peptide/MHC complex, in which the more variable CDR3 loops of the ol and B TCR chains contact the peptide lying in the groove of the MHC molecule, whereas the CDR1 and CDR2 loops contact the a-helices of MHC. Several studies support a role for critical contacts between peptide and CDR3 ol and ~ residues of the TCR (for a review see reference 2). Indirect evidence suggesting contacts between TCR and MHC molecules has been obtained by mutating MHC residues (38) (39) (40) (41) (42) . Multiple residues on one or both ol-helices of the MHC molecules are likely to be simultaneously recognized by the TCR, but the sites of these interactions are not fixed, since different TCRe specific for the same peptide/MHC complex can be differentially affected by mutations of MHC residues (38, 40, 42) . The nature of the MHC/TCR interaction has also been investigated by mutating the CDR regions of the TCR (10-12). Recently, Nalefski et al. (11) U/ml
* The murine 9.4 T hybridoma expressing the wild type Cw3/1.1 TCR (V~10 +) was activated by toxin SAg, as described in Materials and Methods. The results of one out of three independent experiments is shown. The murine T hybridoma DO. 11.10 (VB1 + and V~8.2 +), that express equivalent levels of the TCR/CD3 complex, respond to ExT and SEC2 secreting significant amounts of IL-2 (>50 and >290 U/ml, respectively) presented by all the HLA-DR alleles tested. * L fibroblasts transfected with different HLA-DR alleles (31) were used as presenting cells. All L cell lines express similar levels of HLA-DR (data not shown). $ Only polymorphic residues lying on the c~-helices of the DRB chain are shown. Sequences are from reference 54. 11 II.-2 production was measured using the CTLL-2 assay, as described in Materials and Methods. The IL-2 secreted in response to L cells alone equal CTLL background in all experiments. ExT and SEC2 were used at 10/xg/ml final concentration. laterally to the MHC II molecule (at a distance from the peptide binding groove) and to the lateral exposed face of the V/3 domain, promoting contact between TCR and MHC surfaces. Experimental data on exogenous SAg binding to MHC molecules (44) and on the role of the Vfl CDR4 region in SAg recognition (for reviews see references 45 and 46) have provided some support to these predictions. Evidence for the involvement of other components of the TCR during SAg/MHC II complex recognition has also been reported (20) (21) (22) (23) .
The role of the TCR/3 CDR1 region in the recognition of both peptide/MHC I and SAg/MHC II complexes by a class I-restricted TCR thus far had not been evaluated, and was the purpose of this study. By site-directed mutagenesis, we prepared alanine substitutions at all CDR1 positions of a V/3 domain and the mutants were transfected into an appropriate hybridoma. All mutants could be expressed at a comparable level, and it appears unlikely that the alanine substitutions in the CDR1 13 region disrupted the overall conformation of the TCR for several reasons. In general, protein structures appear quite stable with regard to alanine single point substitutions, especially in loop structures (47, 48) . The most profound effects on ligand binding are invariably found with mutations alterating ligand-contacting residues (47) . The fact that all the CDR1 mutants (except G28A) responded to an anti-V/J10 mAb in the same dose-dependent way as to an anti-Cfl mAb, strongly suggests that the overall structure of the TCR is conserved. Further evidence that alanine mutation in residues T26, L27, and H29 is not causing conformational changes, is the fact that mutations at these positions have no effect on the recognition of at least one of the SAg tested.
We first analyzed the recognition of the complex made of K d and a specific peptide. This revealed that all the residues of the CDR1/3 region are substantially involved, in particular residues 28 to 31, the mutation of which completely disrupted recognition. A role for the charged (H29 and D30) and polar (T31) residues is compatible with previous observations based upon the occurrence of individual amino acids in presumptive functional subregions of the TCR o~ and B chains and class I MHC molecules (49) . The results suggested that the interaction between TCR and MHC molecules would be mediated mainly by charged and polar aromatic residues. Histidines display a remarkably high occurrence in the CDR1 ~ region (49) . It is unlikely, however that these histidines are essential for the local conformation of the binding loop, at least in the TCR studied here, because the alanine substitution at residue H29 did not affect response to the ExT SAg. Glycine 28 may confer a greater flexibility to the CDR1 loop. Note that, although the G28A mutation abolished the specific peptide/MHC I recognition, it significantly increased the responsiveness to an anti-VB10 mAb and the recognition of both toxin-SAg/MHC II complexes. This result shows the different participation of the G28 residue during the engagement of one or the other type of compIex.
We then studied the recognition of SAg/MHC complexes by exposing the hybridomas expressing the various mutants to HLA-DR1 + cells and either SEC2 or Ext superantigens. All mutations (except G28A) diminished the recognition of at least one of the SAg/DR complexes. There are at least two possible explanations for which the CDR1/3 region could influence toxin recognition. First, recognition of SAg may be critically dependent on concomitant recognition of the MHC II molecule by the TCR. Second, the CDR1 region may contact SAg directly. The two hypotheses are not mutually exclusive, and some residues of the CDR1/3 region may contact the MHC II molecule whereas others may contact the SAg.
The SEC2 toxin has high homology to other S. aureus enterotoxins, for which more data on MHC II binding and TCR recognition are available (15, 45) . For the exfoliating toxins, however, the matter of relatedness is much less dear (14) , and data on MHC II and TCR binding are scarce. SEC2 and ExT may bind to the same or overlapping sites on the MHC II molecules as demonstrated for other toxins (50) . It is interesting to note that the analysis of SAg recognition by the mutants described here indicates that the recognition of SEC2 and ExT by the Cw3/1.1 V~10 TCR does not involve the same CDR1 ~/residues. In fact, whereas the recognition of one of the SAg was not affected by mutations at residues T26, V3 CDR1 of MHC I-restricted TCR Recognizes Peptide/MHC I and SAg/MHC II L27, and H29, the recognition of the other toxin was significantly diminished by the same mutation. The unrelatedness between SEC2 and ExT can explain these results. The direct contact between the CDR1 ~ region and toxin SAg was also suggested in a recent study (23) . In addition, evidence for different contact residues in the hypervariable region 4 of V~/8.2 TCR for unrelated endogenous Mls a and bacterial SAg has recently been obtained (20) . L cells transfected with the different HLA-DR alleles were used to present the ExT and SEC2 SAg to the wt Cw3/1.1 TCR-bearing hybridoma 9.4. Both SAg could be presented to the V~10 + 9.4 hybridoma by DRBI*0101, DRBl*1104-F67I, DRBl*1101-F67I, and DRB1*1101, but not by DRBI* 1102, DRBl*1301, or DRBl*1302 (Table 3 ), although all of the different HLA-DR alleles were effective in presenting the same SAg to the Vfl8+/Vfll + DO.11.10 hybridoma (data not shown). Similar results were previously reported by Herman et al. (51) , who have shown that some class II molecules can present SAg to some T cells but not to others that have the proper TCR VB element. Since all HLA-DR molecules share a common cr chain, these results mapped an important site for TCR/MHC II/SAg interaction to the chain of HLA-DR. Moreover, the usage of L cells transfected with different HLA-DR alleles to present ExT or SEC2 is evidence in favor of the role of arginine 71 of the ~ chain of HLA-DR in TCR/MHC II interaction during SAg recognition (Table 3) . Accordingly, the recently resolved crystal of the DR1 molecule (52) indicates that R71 might be oriented towards the peptide binding site and might also be accessible to the TCR.
The observation that mutations at residues D30 and T31 affect to an equal extent the recognition of both toxins, D30 having more drastic effects, is compatible with the view that these CDR1 fl residues interact with the MHC II molecule. Residue D30 is a candidate for the interaction with R71 on the DR molecule, and we are presently investigating this possibility. The great similarity of MHC dass I and II molecules, and the fact that TCR bearing the same V~ elements can recognize both classes of molecules (2), make it possible that the same CDR regions of a TCR may be involved in both type of interactions. So, it is possible that the same CDR1 residues that may contact MHC II in the presence of the SAg, may also contact MHC I in the recognition of peptide/K a complex. Indeed, mutations on D30 and T31 affect both toxin-SAg recognition and also disrupt the recognition of the Cw3 peptide/K d complex. It seems unlikely to us that these two residues would be directly involved both in SAg and peptide contact. We thus suggest that in our system these residues are essential for interaction with both classes of MHC molecules. Whether all the CDR1 residues are contacting only the MHC dass I residues located on the top of o~ helices, or also antigenic peptide residues in our system, needs further investigation.
We thank U. Blank, O. Acuto, and P. Marche for helpful discussion; D. Ojcius and A. Cumano for criticaUy reading the manuscript; and A. Louis and D. Portnoi for expertise in FACS | sorting. We are grateful to R. W. Karr for the gift ofL625.7, L650.2, L663.5, L620.2, L581.13, and L597.2 HLA-DR transfected fibroblast cell lines, and to E. O. Long for the DAP3-DR1 fibroblast line.
M. Bellio was supported by fellowships from Coordena~o de Aperfei~oamento de Pessoal de Nivel Superior (CAPES), Conselho Nacional de Desenvolvimento Cientifico e Tecnol6gico (CNPq) (Brazil), and Association pour la Recherche Sur le Cancer (ARC) (France). O. de la Calle-Martin was supported by a fellowship from INSERM (poste vert).
